Evolving controversies and challenges in the management of opportunistic infections in HIV-seropositive individuals

Journal of Infection

Volumn 63, Issue 3, 2011, Pages 177-186

  Dockrell, David H ^a,b   Edwards, Simon ^c   Fisher, Martin ^d   Williams, Ian ^c   Nelson, Mark ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d Worthing Hospital   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretrovirals; Guidelines; HIV; Opportunistic infections

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ANIDULAFUNGIN; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; BENZIMIDAVIR; CASPOFUNGIN; ECHINOCANDIN; LINEZOLID; MICAFUNGIN; MOXIFLOXACIN; PERAMIVIR; PLACEBO; PNEUMOCOCCUS VACCINE; POSACONAZOLE; VALGANCICLOVIR; VORICONAZOLE; ZANAMIVIR;

ANEMIA; ASPERGILLOSIS; ATYPICAL MYCOBACTERIOSIS; BACTERIAL COLONIZATION; CD4 LYMPHOCYTE COUNT; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; EARLY DIAGNOSIS; ESOPHAGUS CANDIDIASIS; FEVER; HAEMOPHILUS INFLUENZAE; HEALTH CARE PERSONNEL; HERPES SIMPLEX; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA A; MALARIA FALCIPARUM; MYCOSIS; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PSEUDOMONAS INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV SEROPOSITIVITY; HUMANS;

EID: 80052271566     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.05.022     Document Type: Review

References (101)

1. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998 Mar 26, 338(13):853-860.
2. Mocroft A., Sabin C.A., Youle M., Madge S., Tyrer M., Devereux H., et al. Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. J Acquir Immune Defic Syndr 1999 Aug 15, 21(5):401-407.
3. Mocroft A., Katlama C., Johnson A.M., Pradier C., Antunes F., Mulcahy F., et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000 Jul 22, 356(9226):291-296.
4. Detels R., Tarwater P., Phair J.P., Margolick J., Riddler S.A., Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001 Feb 16, 15(3):347-355.
5. Whitehorn J., Edwards S.G., Cartledge J.D., Miller R.F. Outcome of HIV-infected patients transferred to a specialist inpatient unit. Int J STD AIDS 2011 Apr, 22(4):225-227.
6. Kaplan J.E., Benson C., Holmes K.H., Brooks J.T., Pau A., Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the national Institutes of health, and the HIV medicine association of the infectious diseases Society of America. MMWR Recomm Rep 2009 Apr 10, 58(RR-4):1-207. quiz CE1-4.
7. Nelson M, Dockrell D, Edwards S, BHIVA Guidelines Subcommittee. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive Individuals 2011. HIV Medicine, in press.
8. Phillips A., Pezzotti P. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004 Jan 2, 18(1):51-58.
9. Sabin C.A., Smith C.J., Gumley H., Murphy G., Lampe F.C., Phillips A.N., et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004 Nov 5, 18(16):2145-2151.
10. Harte D., Dosekun O., Sethi G., Chadborn T., de Ruiter A., Copas A., et al. Immunosuppression among HIV-1-positive patients attending for care: experience from two large HIV centres in the United Kingdom. HIV Med Feb 2010, 11(2):114-120.
11. Wood E., Hogg R.S., Yip B., Moore D., Harrigan P.R., Montaner J.S. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. AIDS 2006 May 12, 20(8):1117-1123.
12. Buchacz K., Baker R.K., Palella F.J., Chmiel J.S., Lichtenstein K.A., Novak R.M., et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS Jun 19 2010, 24(10):1549-1559.
13. HIV in the United Kingdom: 2010 report. Health Prot Rep 2010, 4(47):1-12. Hpa.
14. last accessed May 29, 2011. http://www.hpa.org.uk/NewsCentre/NationalPressReleases/2009PressReleases/091127AthirdofHIVpatientsdiagnosedlate/.
15. UK national guidelines for HIV testing 2008 last accessed May29,2011. http://www.bhiva.org/documents/Guidelines/Testing/GlinesHIVTest08.pdf/.
16. Keiser O., Anastos K., Schechter M., Balestre E., Myer L., Boulle A., et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008 Jul, 13(7):870-879.
17. Grubb J.R., Moorman A.C., Baker R.K., Masur H. The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 2006 May 12, 20(8):1095-1107.
18. Pulvirenti J., Muppidi U., Glowacki R., Cristofano M., Baker L. Changes in HIV-related hospitalizations during the HAART era in an inner-city hospital. AIDS Read 2007 Aug, 17(8):390-394. 7-401.
19. Smit C., Geskus R., Walker S., Sabin C., Coutinho R., Porter K., et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006 Mar 21, 20(5):741-749.
20. Jordano Q., Falco V., Almirante B., Planes A.M., del Valle O., Ribera E., et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004 Jun 1, 38(11):1623-1628.
21. Kourtis A.P., Ellington S., Bansil P., Jamieson D.J., Posner S.F. Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine. J Acquir Immune Defic Syndr Sep 1 2010, 55(1):128-131.
22. Sjostrom K., Spindler C., Ortqvist A., Kalin M., Sandgren A., Kuhlmann-Berenzon S., et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006 Feb 15, 42(4):451-459.
23. Feldman C., Glatthaar M., Morar R., Mahomed A.G., Kaka S., Cassel M., et al. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Chest 1999 Jul, 116(1):107-114.
24. Flannery B., Heffernan R.T., Harrison L.H., Ray S.M., Reingold A.L., Hadler J., et al. Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006 Jan 3, 144(1):1-9.
25. Grau I., Ardanuy C., Linares J., Podzamczer D., Schulze M.H., Pallares R., et al. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med 2009 Sep, 10(8):488-495.
26. Dropulic L.K., Leslie J.M., Eldred L.J., Zenilman J., Sears C.L. Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS. J Infect Dis 1995 Apr, 171(4):930-937.
27. Cordero E., Pachon J., Rivero A., Giron J.A., Gomez-Mateos J., Merino M.D., et al. Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Clin Infect Dis 2000 Mar, 30(3):461-465.
28. von Gottberg A., de Gouveia L., Madhi S.A., du Plessis M., Quan V., Soma K., et al. Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ 2006 Oct, 84(10):811-818.
29. Sanchez T.H., Brooks J.T., Sullivan P.S., Juhasz M., Mintz E., Dworkin M.S., et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis 2005 Dec 1, 41(11):1621-1627.
30. Fine A.D., Bridges C.B., De Guzman A.M., Glover L., Zeller B., Wong S.J., et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001 Jun 15, 32(12):1784-1791.
31. Boschini A., Longo B., Caselli F., Begnini M., De Maria C., Ansaldi F., et al. An outbreak of influenza in a residential drug-rehabilitation community. J Medical Virology 2006 Sep, 78(9):1218-1222.
32. Madhi S.A., Ramasamy N., Bessellar T.G., Saloojee H., Klugman K.P. Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr Infectious Disease Journal 2002 Apr, 21(4):291-297.
33. Casper C., Englund J., Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood Feb 18 2010, 115(7):1331-1342.
34. Kofla G., Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother 2005 Jun, 6(7):1215-1229.
35. Nagappan V., Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007 Dec 15, 45(12):1610-1617.
36. Metcalf S.C., Dockrell D.H. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infection 2007 Oct, 55(4):287-299.
37. Ally R., Schurmann D., Kreisel W., Carosi G., Aguirrebengoa K., Dupont B., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001 Nov 1, 33(9):1447-1454.
38. Vazquez J.A., Skiest D.J., Nieto L., Northland R., Sanne I., Gogate J., et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006 Apr 15, 42(8):1179-1186.
39. Villanueva A., Gotuzzo E., Arathoon E., Noriega L., Kartsonis N., Lupinacci R., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002 Sep, 113(4):294.
40. Krause D.S., Simjee A.E., van Rensburg C., Viljoen J., Walsh T.J., Goldstein B.P., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004 Sep 15, 39(6):770-775.
41. de Wet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E.F., Della Negra M., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004 Sep 15, 39(6):842-849.
42. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 Aug 8, 347(6):408-415.
43. Ampel N.M. Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis 2005 Oct 15, 41(8):1174-1178.
44. Pescovitz M.D., Rabkin J., Merion R.M., Paya C.V., Pirsch J., Freeman R.B., et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000 Oct, 44(10):2811-2815.
45. Martin D.F., Sierra-Madero J., Walmsley S., Wolitz R.A., Macey K., Georgiou P., et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002 Apr 11, 346(15):1119-1126.
46. Lalezari J., Lindley J., Walmsley S., Kuppermann B., Fisher M., Friedberg D., et al. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr 2002 Aug 1, 30(4):392-400.
47. De Clercq E. Antiviral drug discovery and development: where chemistry meets with biomedicine. Antivir Res 2005 Aug, 67(2):56-75.
48. Husak R., Tebbe B., Goerdt S., Wolfer L.U., Zeichardt H., Stoffler-Meilicke M., et al. Pseudotumour of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient. Br J Dermatol 1998 Jul, 139(1):118-121.
49. Drew W.L., Miner R.C., Marousek G.I., Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006 Oct, 37(2):124-127.
50. Lalezari J.P., Aberg J.A., Wang L.H., Wire M.B., Miner R., Snowden W., et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002 Sep, 46(9):2969-2976.
51. Marty F.M., Ljungman P., Papanicolaou G.A., Winston D.J., Chemaly R.F., Strasfeld L., et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis Apr 2011, 11(4):284-292.
52. Franco-Paredes C., Hidron A., Tellez I., Lesesne J., Del Rio C. HIV infection and travel: pretravel recommendations and health-related risks. Top HIV Med 2009 Feb-Mar, 17(1):2-11.
53. Sherrard A.W., McCarthy A.E. Travel patterns and health risks for patients infected with HIV. Travel Med Infect Dis 2009 Sep, 7(5):291-295.
54. Simons F.M., Cobelens F.G., Danner S.A. Common health problems in HIV-infected travelers to the (sub)tropics. J Travel Med 1999 Jun, 6(2):71-75.
55. Igreja R.P. Pre-travel health advice for human immunodeficiency virus-infected travelers, from Rio de Janeiro. Rev Soc Bras Med Trop 2009 May-Jun, 42(3):260-263.
56. Kemper C.A., Linett A., Kane C., Deresinski S.C. Travels with HIV: the compliance and health of HIV-infected adults who travel. Int J STD AIDS 1997 Jan, 8(1):44-49.
57. Salit I.E., Sano M., Boggild A.K., Kain K.C. Travel patterns and risk behaviour of HIV-positive people travelling internationally. CMAJ 2005 Mar 29, 172(7):884-888.
58. Schuhwerk M.A., Richens J., Zuckerman J.N. HIV and travel. Travel Med Infect Dis 2006 May-Jul, 4(3-4):174-183.
59. Albrecht H., Sobottka I., Emminger C., Jablonowski H., Just G., Stoehr A., et al. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med 1996 Feb, 120(2):189-198.
60. Antinori S., Magni C., Nebuloni M., Parravicini C., Corbellino M., Sollima S., et al. Histoplasmosis among human immunodeficiency virus-infected people in Europe: report of 4 cases and review of the literature. Medicine (Baltimore) 2006 Jan, 85(1):22-36.
61. Diazgranados C.A., Saavedra-Trujillo C.H., Mantilla M., Valderrama S.L., Alquichire C., Franco-Paredes C. Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis 2009 May, 9(5):324-330.
62. Karp C.L., Auwaerter P.G. Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens. Clin Infect Dis 2007 Nov 1, 45(9):1208-1213.
63. Norman F.F., Martin-Davila P., Fortun J., Dronda F., Quereda C., Sanchez-Sousa A., et al. Imported histoplasmosis: two distinct profiles in travelers and immigrants. J Travel Med 2009 Jul-Aug, 16(4):258-262.
64. Walker M., Zunt J.R. Parasitic central nervous system infections in immunocompromised hosts. Clin Infect Dis 2005 Apr 1, 40(7):1005-1015.
65. Bottieau E., Florence E., Clerinx J., Vlieghe E., Vekemans M., Moerman F., et al. Fever after a stay in the tropics: clinical spectrum and outcome in HIV-infected travelers and migrants. J Acquir Immune Defic Syndr 2008 Aug 15, 48(5):547-552.
66. Lopez-Velez R., Huerga H., Turrientes M.C. Infectious diseases in immigrants from the perspective of a tropical medicine referral unit. Am J Trop Med Hyg 2003 Jul, 69(1):115-121.
67. Grimwade K., French N., Mbatha D.D., Zungu D.D., Dedicoat M., Gilks C.F. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 2004 Feb 20, 18(3):547-554.
68. Smith A.D., Bradley D.J., Smith V., Blaze M., Behrens R.H., Chiodini P.L., et al. Imported malaria and high risk groups: observational study using UK surveillance data 1987-2006. BMJ 2008, 337:a120.
69. Lalloo D.G., Shingadia D., Pasvol G., Chiodini P.L., Whitty C.J., Beeching N.J., et al. UK malaria treatment guidelines. J Infect 2007 Feb, 54(2):111-121.
70. Dondorp A., Nosten F., Stepniewska K., Day N., White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005 Aug 27-Sep 2, 366(9487):717-725.
71. White N.J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997 Jul, 41(7):1413-1422.
72. Newton P.N., Ward S., Angus B.J., Chierakul W., Dondorp A., Ruangveerayuth R., et al. Early treatment failure in severe malaria resulting from abnormally low plasma quinine concentrations. Trans R Soc Trop Med Hyg 2006 Feb, 100(2):184-186.
73. Soyinka J.O., Onyeji C.O., Omoruyi S.I., Owolabi A.R., Sarma P.V., Cook J.M. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol Mar 2010, 69(3):262-270.
74. Soyinka J.O., Onyeji C.O., Omoruyi S.I., Owolabi A.R., Sarma P.V., Cook J.M. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol 2009 Apr, 61(4):439-443.
75. German P., Parikh S., Lawrence J., Dorsey G., Rosenthal P.J., Havlir D., et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009 Aug 1, 51(4):424-429.
76. Grabar S., Le Moing V., Goujard C., Leport C., Kazatchkine M.D., Costagliola D., et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000 Sep 19, 133(6):401-410.
77. Ledergerber B., Mocroft A., Reiss P., Furrer H., Kirk O., Bickel M., et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European study groups. N Engl J Med 2001 Jan 18, 344(3):168-174.
78. Lopez Bernaldo de Quiros J.C., Miro J.M., Pena J.M., Podzamczer D., Alberdi J.C., Martinez E., et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001 Jan 18, 344(3):159-167.
79. Kirk O., Reiss P., Uberti-Foppa C., Bickel M., Gerstoft J., Pradier C., et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002 Aug 20, 137(4):239-250.
80. Miro J.M., Lopez J.C., Podzamczer D., Pena J.M., Alberdi J.C., Martinez E., et al. Discontinuation of primary and secondary toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis 2006 Jul 1, 43(1):79-89.
81. Soriano V., Dona C., Rodriguez-Rosado R., Barreiro P., Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000 Mar 10, 14(4):383-386.
82. Aberg J.A., Williams P.L., Liu T., Lederman H.M., Hafner R., Torriani F.J., et al. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated mycobacterium avium complex: AIDS clinical trial group 393 study team. J Infect Dis 2003 Apr 1, 187(7):1046-1052.
83. Zeller V., Truffot C., Agher R., Bossi P., Tubiana R., Caumes E., et al. Discontinuation of secondary prophylaxis against disseminated mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002 Mar 1, 34(5):662-667.
84. Rossi M., Flepp M., Telenti A., Schiffer V., Egloff N., Bucher H., et al. Disseminated M. avium complex infection in the Swiss HIV cohort study: declining incidence, improved prognosis and discontinuation of maintenance therapy. Swiss Med Wkly 2001 Aug 11, 131(31-32):471-477.
85. Martinez E., Garcia-Viejo M.A., Marcos M.A., Perez-Cuevas J.B., Blanco J.L., Mallolas J., et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000 Nov 10, 14(16):2615-2617.
86. Mussini C., Pezzotti P., Miro J.M., Martinez E., de Quiros J.C., Cinque P., et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004 Feb 15, 38(4):565-571.
87. Vibhagool A., Sungkanuparph S., Mootsikapun P., Chetchotisakd P., Tansuphaswaswadikul S., Bowonwatanuwong C., et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003 May 15, 36(10):1329-1331.
88. Casado J.L., Lopez-Velez R., Pintado V., Quereda C., Antela A., Moreno S. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001 Mar, 20(3):202-205.
89. Mocroft A., Reiss P., Kirk O., Mussini C., Girardi E., Morlat P., et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?. Clin Infect Dis Sep 1 2010, 51(5):611-619.
90. Cheng C.Y., Chen M.Y., Hsieh S.M., Sheng W.H., Sun H.Y., Lo Y.C., et al. Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2010, 10:126.
91. Shelburne S.A., Visnegarwala F., Darcourt J., Graviss E.A., Giordano T.P., White A.C., et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005 Mar 4, 19(4):399-406.
92. French M.A. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009 Jan 1, 48(1):101-107.
93. Muller M., Wandel S., Colebunders R., Attia S., Furrer H., Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis Apr 2010, 10(4):251-261.
94. Zolopa A., Andersen J., Powderly W., Sanchez A., Sanne I., Suckow C., et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009, 4(5):e5575.
95. Grant P.M., Komarow L., Andersen J., Sereti I., Pahwa S., Lederman M.M., et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One 2010, 5(7):e11416.
96. Makadzange A.T., Ndhlovu C.E., Takarinda K., Reid M., Kurangwa M., Gona P., et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis Jun 1 2010, 50(11):1532-1538.
97. Brouwer A.E., Rajanuwong A., Chierakul W., Griffin G.E., Larsen R.A., White N.J., et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004 May 29, 363(9423):1764-1767.
98. Menichetti F., Fiorio M., Tosti A., Gatti G., Bruna Pasticci M., Miletich F., et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996 May, 22(5):838-840.
99. Shelburne S.A., Darcourt J., White A.C., Greenberg S.B., Hamill R.J., Atmar R.L., et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005 Apr 1, 40(7):1049-1052.
100. Bicanic T., Meintjes G., Rebe K., Williams A., Loyse A., Wood R., et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009 Jun 1, 51(2):130-134.
101. Boulware D.R., Meya D.B., Bergemann T.L., Wiesner D.L., Rhein J., Musubire A., et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 2010, 7(12):e1000384.